Valpres

Valpres

valsartan

Manufacturer:

Novartis

Distributor:

Zuellig Pharma
Concise Prescribing Info
Contents
Valsartan
Indications/Uses
HTN. Heart failure (NYHA class II-IV) in patients receiving standard therapy eg, diuretics, digitalis & either ACE inhibitors or β-blockers but not both. Post-MI, in clinically stable patients w/ signs, symptoms or radiological evidence of left ventricular failure &/or w/ left ventricular dysfunction.
Dosage/Direction for Use
HTN 80 mg or 160 mg once daily. May be increased to 320 mg, or add a diuretic if BP is not adequately controlled. Heart failure 40 mg bid. May be uptitrated to 80 mg & 160 mg bid as tolerated. Max daily dose: 320 mg in divided doses. Post-MI Initially 20 mg bid as early as 12 hr after MI. Titrate to 40 mg, 80 mg, & 160 mg bid over the next few wk, or until a dose level of 80 mg bid 2 wk after treatment initiation is achieved. Target max dose in 3 mth: 160 mg bid.
Administration
May be taken with or without food.
Contraindications
Hypersensitivity. Concomitant use of angiotensin receptor antagonists or ACE inhibitors w/ aliskiren in patients w/ type 2 diabetes. Pregnancy.
Special Precautions
Correct Na &/or vol depletion prior to starting treatment. Monitor BUN & serum creatinine in patients w/ bilateral or unilateral renal artery stenosis. Patients w/ biliary obstructive disorders; heart failure or post-MI; evaluation of patients w/ heart failure or post-MI should always include renal function assessment. Concomitant use w/ ACE inhibitors & β-blocker in patients w/ heart failure. Discontinue if angioedema occurs. Concomitant use w/ drugs that block renin-angiotensin system eg, ACE inhibitors or aliskiren. Avoid concomitant use w/ aliskiren in patients w/ severe renal impairment (GFR <30 mL/min). Women of childbearing potential. Lactation.
Adverse Reactions
Dizziness, postural dizziness; hypotension, orthostatic hypotension; renal failure & impairment.
Drug Interactions
Increased incidence of hypotension, hyperkalemia & renal function changes w/ other drugs acting on renin-angiotensin system (eg, ARBs, ACE inhibitors, or aliskiren). Increased serum K & creatinine w/ K-sparing diuretics (eg, spironolactone, triamterene, amiloride), K supplements, or K-containing salt substitutes or other K level increasing drugs. Attenuated antihypertensive effect may occur w/ NSAIDs including selective cyclooxygenase-2 inhibitors. May increase serum lithium conc & toxicity. Increased systemic exposure w/ hepatic uptake transporter OATP1B1 inhibitors (eg, rifampin, cyclosporine) & hepatic efflux transporter MRP2 inhibitors (eg, ritonavir).
ATC Classification
C09CA03 - valsartan ; Belongs to the class of angiotensin II receptor blockers (ARBs). Used in the treatment of cardiovascular disease.
Presentation/Packing
Form
Valpres FC tab 160 mg
Packing/Price
28's
Form
Valpres FC tab 80 mg
Packing/Price
28's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in